厦门艾德生物医药科技股份有限公司 累积投票制度实施细则 厦门艾德生物医药科技股份有限公司 累积投票制度实施细则 第一条 为进一步完善厦门艾德生物医药科技股份有限公司（以下简称"公 司"）法人治理结构，规范公司董事的选举，保证股东充分行使权利，根据《中 华人民共和国公司法》《上市公司治理准则》等有关法律、法规、规范性文件及 《厦门艾德生物医药科技股份有限公司章程》（以下简称《公司章程》）及其他有 关规定，特制订本实施细则。 第二条 本实施细则适用于股东会选举或变更二名及以上董事（包括非独立 董事、独立董事）的议案。董事会中的职工代表董事由公司职工通过职工代表大 会或者其他形式民主选举产生，不适用本实施细则的相关规定。 第三条 本实施细则所称的累积投票制度，是指公司股东会选举两名或两名 以上董事时，出席股东会的股东所拥有的投票表决权等于其所持有的股份总数乘 以应选董事人数之积，出席会议股东可以将其拥有的投票表决权全部投向一位董 事候选人，也可以将其拥有的投票表决权分散投向多位董事候选人，按得票多少 依次决定董事人选。 第四条 实行累积投票制选举公司董事时，为确保独立董事当选符合规定， 公司独立董事和非独立董事的选 ...

厦门艾德生物医药科技股份有限公司 关联交易决策制度 厦门艾德生物医药科技股份有限公司 关联交易决策制度 第一条 为规范厦门艾德生物医药科技股份有限公司（以下简称"公司"或 "本公司"）及其控股子公司与公司关联人之间的关联交易决策程序，确保关联 交易不损害公司和非关联股东的合法权益，根据《中华人民共和国公司法》《深 圳证券交易所创业板股票上市规则》等法律法规及《厦门艾德生物医药科技股份 有限公司章程》（以下简称"公司章程"）的规定，制定本制度。 第二条 本制度所称关联交易是指本公司或本公司控股子公司与公司关联人 之间发生的转移资源或义务的事项。包括下列事项： （一）购买或者出售资产； （二）对外投资（含委托理财、对子公司投资等，设立或者增资全资子公司 除外）； （三）提供财务资助（含委托贷款）； 第三条 本制度所称关联人包括关联法人和关联自然人。 1 （四）提供担保（含公司为他人提供的担保，含对控股子公司的担保）； （五）租入或者租出资产； （六）签订管理方面的合同（含委托经营、受托经营等）； （七）赠与或者受赠资产； （八）债权或者债务重组； （九）研究与开发项目的转移； （十）签订许可协议； （十一）放弃权 ...

（文章来源：证券日报） 证券日报网讯 12月8日晚间，艾德生物发布公告称，公司近日取得中国国家知识产权局颁发的发明专利 证书，专利名称为"FFPE样本中核酸的自动化提取方法"。 ...

Core Viewpoint - Major international institutions, including JPMorgan, Morgan Stanley, and UBS, express confidence in the outlook for China's economy and capital markets in 2026, highlighting the increasing medium- to long-term investment value of the Chinese stock market [2][9]. Group 1: JPMorgan's Insights - JPMorgan raises its rating for A-shares to "overweight," predicting a significant probability of market growth in 2026, with the MSCI China Index target price set at 100 points and the CSI 300 Index potentially reaching 5200 points (optimistically up to 6000 points) [2]. - Four key investment themes identified by JPMorgan include: 1. Acceleration of "anti-involution" policies, with significant room for improvement in net profit margins and ROE in the MSCI China Index [2]. 2. Opportunities arising from the expansion of AI infrastructure, benefiting domestic supply chain companies and those focused on domestic substitution and AI commercialization [3]. 3. Recovery of the global macro environment supporting external demand growth, aided by easing fiscal and monetary policies in major economies [4]. 4. A "K-shaped recovery" in consumption, where food and beverage and luxury goods sectors continue to benefit, while mid-tier consumption faces pressure [5]. Group 2: UBS's Perspective - UBS anticipates a positive turning point for A-shares, with earnings growth accelerating from 6% this year to 8% next year, driven by faster nominal GDP growth and a narrowing decline in PPI [9]. - The firm emphasizes the potential for significant valuation recovery in A-shares, suggesting that recent market pullbacks present a good opportunity for mid-term positioning [9]. - Key investment themes recommended by UBS include technological independence, consumption recovery, sectors benefiting from "anti-involution" (such as photovoltaics, lithium batteries, and chemicals), and Chinese companies expanding overseas [9]. Group 3: Morgan Stanley and Goldman Sachs - Morgan Stanley highlights that the Chinese stock market has completed a decisive valuation repair, with the MSCI China Index's P/E ratio recovering from 9 times to over 13 times, suggesting limited room for further valuation expansion in 2026 [12]. - Goldman Sachs notes that recent policies boosting consumption and technological innovation enhance the attractiveness of the Chinese market, emphasizing the importance of stock selection to achieve sustainable profit growth [12]. Group 4: Target Price Adjustments - JPMorgan has adjusted ratings for 34 A-share companies since October, maintaining "overweight" ratings for 17, "underweight" for 3, and "neutral" for 12, with notable target price increases for companies like OmniVision Technologies, which has a target price of 186 CNY per share, indicating over 55% upside potential from its recent closing price [6][8]. - UBS has also adjusted ratings for 196 A-share companies, maintaining "buy" ratings for 131 and upgrading 4 to "buy," with a target price for Aibo Medical set at 118 CNY per share, suggesting over 90% upside potential from its recent closing price [10].

（文章来源：证券日报） 证券日报网讯 12月8日，艾德生物在互动平台回答投资者提问时表示，公司目前生产经营活动正常。 BD部门将持续推进与包括礼来在内的国内外知名药企在伴随诊断领域的合作。 ...

Core Viewpoint - The Biotech Index (970038) closed at 2128.92 points, down 0.19%, with a trading volume of 12.11 billion yuan and a turnover rate of 0.9% [1] Group 1: Index Performance - On the day, 17 stocks in the Biotech Index rose, with Deep Technology leading at a 2.97% increase, while 31 stocks fell, with Palin Bio leading the decline at 1.77% [1] - The top ten constituent stocks of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58% and a latest price of 200.05, down 1.16% [1] - Changchun High-tech (sz000661) with a weight of 4.87% and a latest price of 99.20, down 0.53% [1] - Other notable stocks include Kanglong Chemical (sz300759), Biao Ge Medical (sz300347), and Deep Technology (sz000021) [1] Group 2: Capital Flow - The Biotech Index constituents experienced a net outflow of 197 million yuan from main funds, while retail investors saw a net inflow of 47.17 million yuan [3] - Deep Technology (000021) had a main fund net inflow of 148 million yuan, while other stocks like Aide Bio (300685) and Jingxin Pharmaceutical (002020) faced net outflows from main and retail funds [3] Group 3: Index Adjustments - Recent adjustments to the Biotech Index included the addition of 9 stocks and the removal of 9 stocks [3] - New stocks added include: - Chaoyan Co. (301602) with a market cap of 9.783 billion yuan [4] - Kanghua Bio (300841) with a market cap of 10.631 billion yuan [4] - Stocks removed include: - Wens Foodstuffs (300498) with a market cap of 120.303 billion yuan [4] - Red Sun Pharmaceutical (002020) with a market cap of 17.066 billion yuan [4]

艾德生物公告，近日获得中国国家知识产权局颁发的1项发明专利证书。发明专利名称为"FFPE样本中 核酸的自动化提取方法"，专利号为ZL201810622261.5，专利申请日为2018年6月15日，授权公告日为 2025年12月2日。该专利为公司自主研发，已在相关产品上应用。取得该专利不会对近期生产经营产生 重大影响，但有利于完善知识产权保护体系，促进技术创新，提升公司综合实力。 ...

厦门艾德生物医药科技股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）于近 日获得中国国家知识产权局颁发的1项发明专利证书。具体情况如下 发明专利名称：FFPE样本中核酸的自动化提取方法 专利号：ZL 2018 1 0622261.5 专利类型：发明 专利申请日：2018年6月15日 证券代码：300685 证券简称：艾德生物 公告编号：2025-062 授权公告日：2025年12月2日 专利权期限：自申请日起二十年 专利权人：厦门艾德生物医药科技股份有限公司 上述发明专利为公司自主研发，已在公司相关产品上应用。上述专利的取得 不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识产权保护 体系，充分发挥自主知识产权优势，促进技术创新，提升公司的综合实力。 厦门艾德生物医药科技股份有限公司 董 事 会 2025 年 12 月 8 日 ...

Core Viewpoint - The medical device sector experienced a slight decline of 0.23% on December 8, with BaiRen Medical leading the losses, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.54% and the Shenzhen Component Index increasing by 1.39% [1] Group 1: Market Performance - The medical device sector's decline was led by BaiRen Medical, which saw a drop of 3.39% in its closing price [2] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Group 2: Individual Stock Performance - ZhenDe Medical (603301) had a closing price of 74.01, with a significant increase of 6.95% and a trading volume of 178,200 shares, amounting to a transaction value of 1.317 billion yuan [1] - Other notable gainers included Rejing Bio (688068) with a closing price of 181.00, up 4.89%, and Huakang Clean (301235) at 31.03, up 4.76% [1] - BaiRen Medical (688188) closed at 111.99, down 3.39%, with a trading volume of 9,959.93 shares and a transaction value of 113 million yuan [2] Group 3: Capital Flow - The medical device sector saw a net outflow of 199 million yuan from institutional investors, while retail investors contributed a net inflow of 213 million yuan [2] - The capital flow data indicates that ZhenDe Medical had a net inflow of 210 million yuan from institutional investors, while retail investors showed a net outflow of 169 million yuan [3]

（文章来源：每日经济新闻） 艾德生物（300685.SZ）12月8日在投资者互动平台表示，公司基于NGS 10基因产品开展的非小细胞肺 癌驱动基因阳性患者的多中心真实世界MRD研究，已于12月6日在ESMO-Asia会议上进行口头报告。在 研产品的获批情况请以公司公告为准。 每经AI快讯，有投资者在投资者互动平台提问：请问公司有哪些MRD产品和在研项目？ ...